Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ELC200 · 4 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| ELC200 (carbidopa+levodopa+entacapone) | DRUG | - |
Inclusion Criteria: * Healthy male and female subjects age 18 to 55 years of age included, and in good health * At Screening, and Baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed after the subject has rested for at least five (5) minutes, and again when ...
ELC200 is a small molecule being developed by Novartis AG for use in healthy volunteers. It is currently in Phase 1 clinical development, with all four completed trials conducted in healthy participants to assess bioequivalence of carbidopa/levodopa/entacapone combinations.
ELC200 is developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker NVS. The drug is currently in Phase 1 clinical development.
ELC200 is in Phase 1 clinical development. All four clinical trials associated with the drug have been completed, with a total enrollment of 168 healthy volunteers across studies conducted in Germany.
ELC200 has been studied in four completed Phase 1 bioequivalence trials: NCT00415740, NCT00415831, NCT00415844, and NCT00415922. Each trial enrolled 42 healthy volunteers in Germany and compared carbidopa/levodopa/entacapone combination formulations.
ELC200 is being studied as a combination product containing carbidopa, levodopa, and entacapone. The clinical trials evaluate the bioequivalence of this combination versus separate administration of carbidopa/levodopa plus entacapone in healthy volunteers.